i-Pharm Consulting’s Post

View organization page for i-Pharm Consulting, graphic

170,154 followers

A new synthetic antibiotic, cresomycin, has shown promising results in early tests against flesh-eating bacteria and other multidrug-resistant pathogens. 💊 Researchers from the University of Illinois Chicago and Harvard University discovered that cresomycin is effective in killing various resistant bacteria strains in cell cultures and mice. This antibiotic works by binding tightly to the bacterial ribosome, disrupting protein synthesis even in bacteria that have developed resistance mechanisms. In tests, cresomycin effectively killed multidrug-resistant bacteria, including those responsible for many healthcare-acquired infections. In mouse models, it significantly improved survival rates and reduced bacterial loads compared to control groups. The research team, supported by a $1.2 million grant from CARB-X, plans to continue developing the compound for potential clinical use. We look forward to seeing how this development in our industry plays out! 💡 #drugdevelopment #iPharm #antibiotic

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics